Bicara Therapeutics Inc. (BCAX), Monday announced the results from the Phase 1/1b dose expansion cohort, evaluating the combination of ficerafusp alfa with pembrolizumab in patients with second-line or later squamous cancer of the anal canal or SCAC.
Among the 28 participants, the study showed a confirmed overall response rate of 25 percent with 6 partial responses and 1 complete response.
The company added that the median progression-free survival or PFS was 2.9 months and the PFS rate at one year was 40.7 percent.
Bicara highlighted that the early data indicate the crucial role of ficerafusp alfa in the future treatment of SCAC.
Currently, Bicara's stock is trading at $12.00, up 3.40 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.